Physician profile
Randall Roy
NPI 1306001383
$3,162.02
in general payments reported to CMS, 2019-2025
11 companies · $204 in 2025
The $204 reported for 2025 was less than what a typical Sports Medicine (Orthopaedic Surgery) provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $167 · 2020: $14.95 · 2021: $1,180 · 2022: $1,596 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $204.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $204.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impactortho, INC. | $1,391.43 | 2022 | |
| Encore Medical, LP | $1,095.02 | 2021 | |
| Vital Orthopedics LLC | $204.19 | 2025 | |
| Depuy Synthes Sales INC. | $196.60 | 2019-2022 | |
| Smith+Nephew, INC. | $89.85 | 2022 | |
| Bioventus LLC | $60.30 | 2019-2021 | |
| Heron Therapeutics, INC. | $49.61 | 2019 | |
| Medtronic USA, INC. | $27.41 | 2019 | |
| Pfizer INC. | $18.98 | 2019 | |
| Pacira Therapeutics, INC. | $18.63 | 2019 | |
| Team_makena_llc | $10.00 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.